Harrow subsidiary ImprimisRx gets new CEO
Source: SeekingAlpha
2025-10-06 07:44:09 ET
More on Harrow Health
- Harrow, Inc. (HROW) Analyst/Investor Day Transcript
- Harrow: Buy A Blend Of Value And Growth
- Harrow: A Classical GARP Stock
- Harrow to buy Melt Pharmaceuticals
- Harrow launches $250M debt offering
Read the full article on Seeking Alpha
For further details see:
Harrow subsidiary ImprimisRx gets new CEO
Harrow Health Inc.
NASDAQ: HROW
HROW Trading
-4.58% G/L:
$33.77 Last:
418,081 Volume:
$35.80 Open:
